Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
June 09 2022 - 7:00AM
Business Wire
- Data suggest Piclidenoson and Namodenoson could potentially
be the first A3AR agonists to achieve FDA approval and provide
clinicians with new oral and safe drugs in the arsenal for fighting
psoriasis, liver cancer, and NASH
- Can-Fite is a global leader in the development of small
molecule A3AR drugs with an ongoing Phase IIb NASH study, a pivotal
Phase III liver cancer study open for enrollment, and topline data
expected from a completed Phase III psoriasis study in Q2
2022
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver
diseases, today announced an article titled “Drugs Targeting the A3
Adenosine Receptor: Human Clinical Study Data” was published in
MDPI’s open access scholarly journal Molecules. The complete
article can be accessed here: LINK
Can-Fite is a global leader in the development of small molecule
A3 adenosine receptor (A3AR) technology with 15 patent families,
extensive efficacy and safety data in over 1,500 patients, and
three indications in Phase II and III studies.
In the scientific community, A3AR is well established as a
target for combatting inflammation and cancer. The target, Gi
protein-coupled A3AR, is highly expressed in inflammatory and
cancer cells, but not in normal cells. High A3AR expression is also
found in peripheral blood mononuclear cells (PBMCs) of patients
with inflammatory diseases and cancer, reflecting A3AR expression
in pathological remote sites. Solid tumor cells including breast,
colon, small cell lung, pancreatic carcinoma, and melanoma, highly
express A3AR compared to normal adjacent tissue cells. A3AR is also
expressed in inflammatory cells such as synoviocytes derived from
patients with rheumatoid arthritis, skin biopsies, and PBMCs from
psoriasis and Crohn’s disease patients.
Targeting this receptor with synthetic and highly selective A3AR
agonists induces anti-inflammatory and anti-cancer effects.
Can-Fite’s patent estate provides broad coverage for its A3AR
platform technology across numerous indications.
“As a leader in the development of A3AR targeting drugs, we are
pleased to have this comprehensive article published in an
open-source scientific journal. We believe providing data on our
platform’s mechanism of action and its performance in several
clinical studies supports the advancement of knowledge and
discovery specific to A3AR and increases its potential to become a
widely used mechanism to treat chronic and acute disease,” stated
Can-Fite CEO Dr. Pnina Fishman.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson has completed
enrollment in a Phase III trial for psoriasis. Can-Fite's liver
drug, Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of non-alcoholic steatohepatitis (NASH), and a Phase III
trial for hepatocellular carcinoma (HCC), the most common form of
liver cancer. Namodenoson has been granted Orphan Drug Designation
in the U.S. and Europe and Fast Track Designation as a second line
treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat
other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction. These drugs have an excellent safety
profile with experience in over 1,500 patients in clinical studies
to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the impact of the COVID-19 pandemic; the initiation,
timing, progress and results of our preclinical studies, clinical
trials and other product candidate development efforts; our ability
to advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and
the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic
partnerships and other corporate collaborations; the implementation
of our business model and strategic plans for our business and
product candidates; the scope of protection we are able to
establish and maintain for intellectual property rights covering
our product candidates and our ability to operate our business
without infringing the intellectual property rights of others;
competitive companies, technologies and our industry; statements as
to the impact of the political and security situation in Israel on
our business; and risks and other risk factors detailed in
Can-Fite’s filings with the SEC and in its periodic filings with
the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced
by economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220609005293/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024